

### AMENDMENTS TO THE SPECIFICATION

Please insert the Sequence Listing, 12 pages of .txt file, attached hereto, behind the Abstract of the application.

Please amend paragraph number [0066] at page 15 with the paragraph below. The paragraph has been changed to properly identify the sequences contained therein.

[0066] The peptides may also be in the form of oligomers, particularly dimers of the peptides, which may be head to head, tail to tail, or head to tail, there being not more than about 6 repeats of the peptide. The oligomer may contain one or more D-stereoisomer amino acids, up to all of the amino acids. The oligomers may or may not include linker sequences between the peptides. When linker sequences are used, suitable linkers include those comprising uncharged amino acids and (Gly)<sub>n</sub> (SEQ ID NOS:37-40), where n is 1-7, Gly-Ser (e.g., (GS)<sub>n</sub>, (GSGGS)<sub>n</sub> (set forth as SEQ ID NO:29), and (GGGS)<sub>n</sub> (set forth as SEQ ID NO:30), where n is at least 1), Gly-Ala, Ala-Ser, or other flexible linkers, as known in the art. Linkers of Gly or Gly-Ser may be used since these amino acids are relatively unstructured, which allows interaction of individual peptides with cellular target molecules and limits structural perturbations between peptides of the oligomer. It is to be understood that linkers other than amino acids may be used to construct the oligomeric peptides.